Since Ehrlich's discovery of arsphenamine did not accomplish the desired millennium in the treatment of syphilis, scientific workers have been constantly seeking to improve the known methods of attack on this disease. These endeavors have been directed toward better management of the courses of treatment, modifications in the dosage of drugs, variations in the methods of administration and the addition of new chemical compounds. During the past two years we have conducted a clinical study with a new drug in 84 cases of various types of syphilis. An arsenical compound having the common name of acetylglycarsenobenzene was administered intramuscularly, together with an oil-soluble bismuth compound and insoluble mercury. The patients were a selected group who had not received previous antisyphilitic treatment. In each instance the diagnosis of syphilis was supported by a dark field examination or by a serologic test.
Acetylglycarsenobenzene is chemically 3,4′-diacetylamino-4-hydroxyarsenobenzene 2′-sodium glycolate. The molecular weight
GUY WH, GOLDMANN BA, GANNON GP, SLONE J. ACETYLGLYCARSENOBENZENE IN TREATMENT OF SYPHILIS: PRELIMINARY REPORT. Arch Derm Syphilol. 1940;42(6):1046–1058. doi:10.1001/archderm.1940.01490180055004
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: